Evidence map›Paper›PMID 32742197›Full record

ArticleCancer cell international2020

LncRNA FOXD3-AS1 promoted chemo-resistance of NSCLC cells via directly acting on miR-127-3p/MDM2 axis.

Zhaolong Zeng, Guofang Zhao, Huangkai Zhu, Liangqin Nie, Lifeng He, Jiangtao Liu, Rui Li, Shuai Xiao, Gang Hua

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Role of the MDM2/p53 axis in regulating cisplatin response in tumor cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Observational
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Zhaolong Zeng *Department of Thoracic Surgery, Hwamei Hospital, University of Chinese Academy of Sciences, No. 41 Northwest Street, Haishu District, Ningbo City, 315000 Zhejiang Province China.
Guofang Zhao *Department of Thoracic Surgery, Hwamei Hospital, University of Chinese Academy of Sciences, No. 41 Northwest Street, Haishu District, Ningbo City, 315000 Zhejiang Province China.
Huangkai Zhu *School of Medicine, Ningbo University, Ningbo, Zhejiang Province, China.
Liangqin NieDepartment of Radiology, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang Province, China.
Lifeng HeDepartment of Thoracic Surgery, Hwamei Hospital, University of Chinese Academy of Sciences, No. 41 Northwest Street, Haishu District, Ningbo City, 315000 Zhejiang Province China.
Jiangtao LiuDepartment of Spinal Surgery, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang Province, China.
Rui LiDepartment of Thoracic Surgery, Hwamei Hospital, University of Chinese Academy of Sciences, No. 41 Northwest Street, Haishu District, Ningbo City, 315000 Zhejiang Province China.
Shuai XiaoDepartment of Thoracic Surgery, Hwamei Hospital, University of Chinese Academy of Sciences, No. 41 Northwest Street, Haishu District, Ningbo City, 315000 Zhejiang Province China.
Gang HuaDepartment of Thoracic Surgery, Hwamei Hospital, University of Chinese Academy of Sciences, No. 41 Northwest Street, Haishu District, Ningbo City, 315000 Zhejiang Province China.ORCID 0000-0002-7325-4015
Ningbo No. 2 Hospital · CNUniversity of Chinese Academy of Sciences · CNNingbo University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to investigate the mechanism underlying the high level of long non-coding RNA FOXD3-AS1 in cisplatin-resistant NSCLC cells.

methodsCisplatin-resistant cells were generated from A549 cells. CCK-8 were used to evaluate cell proliferation. The FOXD3-AS1, miR-127-3p, MDM2 and MRP1 mRNA expression levels were confirmed by qRT-PCR. Protein levels of MDM2 and MRP1 were determined by western blot assay. Luciferase reporter and RNA pull-down assays were evaluated the relationship between miR-127-3p and FOXD3-AS1/MDM2. In vivo tumor growth was evaluated in a xenograft nude mice model.

resultsFOXD3-AS1 was up-regulated in cisplatin-resistant NSCLC cells (A549/DDP and H1299/DDP cells) in comparison with their parental cell lines. Overexpression of FOXD3-AS1 promoted cisplatin-resistance in A549 and H1299 cells; while FOXD3-AS1 knockdown sensitized A549/DDP and H1299/DDP cells to cisplatin treatment. FOXD3-AS1 regulated miR-127-3p expression by acting as a competing endogenous RNA, and miR-127-3p repressed MDM2 expression via targeting the 3'UTR. MiR-127-3p overexpression and MDM2 knockdown both increased the chemo-sensitivity in A549/DDP cells; while miR-127-3p knockdown and MDM2 overexpression both promoted chemoresistance in A549 cells. Further rescue experiments revealed that miR-127-3p knockdown or MDM2 overexpression counteracted the suppressive effects of FOXD3-AS1 knockdown on chemo-resistance and MRP1 expression in A549/DDP cells. In vivo studies showed that FOXD3-AS1 knockdown potentiated the antitumor effects of cisplatin treatment. Inspection of clinical samples showed the upregulation of FOXD3-AS1 and MDM2, and down-regulation of miR-127-3p in NSCLC tissues compared to normal adjacent tissues.

conclusionIn conclusion, our results suggest that LncRNA FOXD3-AS1 promotes chemo-resistance of NSCLC cells via directly acting on miR-127-3p/MDM2 axis. Our findings may provide novel perspectives for the treatment of NSCLC in patients resistant to chemotherapy.

Indexed as

Chemo-resistanceCisplatinFOXD3-AS1MDM2miR-127-3pNSCLC

Identifiers

PMID32742197
PMCPMC7388492
OpenAlexW3045667391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.